Worth it. Shanghai Securities News China Securities Network News According to the announcement from the exchange, Dizhe Pharmaceuticals subscribed today, subscription code: 787192, issue price: 52.58 yuan/share, single account subscription limit is 7,500 shares, top subscription requires a market value of 75,000 yuan. Dizhe Pharmaceuticals is listed on the Science and Technology Innovation Board, issuing a total of 40.001 million shares, and plans to raise approximately 1.783 billion yuan. It is listed under the fifth set of listing standards of the Science and Technology Innovation Board, with CITIC Securities as its sponsor.
1. The listing of Dizhe (Jiangsu) Pharmaceutical Co., Ltd. ("Dizhe Pharmaceutical") on the Science and Technology Innovation Board has attracted a lot of attention from the market. Investigating further, it may stem from the "origin" of Dizhe Medicine. Founded in 2017, Dizhe Pharmaceutical is a very young biotechnology company. At the beginning of its establishment, the registered capital was US$132.53 million, of which AZAB subscribed US$55 million, accounting for 41.50% of the total registered capital; Advanced Manufacturing subscribed US$55 million, accounting for 41.50%; Wuxi Lingchuang subscribed US$20.54 million, accounting for 15.50% %; ZYTZ subscribed US$1.98 million, accounting for 1.50%.
2. AZAB is a wholly-owned subsidiary of AstraZeneca; the full name of advanced manufacturing is "Advanced Manufacturing Industry Investment Fund", in which the Ministry of Finance holds 36.3% of the shares, which is equivalent to state-owned capital, so Dizhe Pharmaceuticals can be counted as "Sino-foreign joint ventures". The core technical staff of Dizhe Medicine are also from the innovation center. Chief Medical Officer Yang Zhenfan, chief scientists Qingbei Zeng (Zeng Qingbei), HONCHUNG TSUI (Xu Hanzhong), Chen Kan, Zheng Li, etc. were all previous AstraZeneca researchers.
1. Among the management and technical staff of Dizhe Pharmaceutical, as of the end of 2020, ***55 have worked for AstraZeneca; among them, the founding team, senior managers and other important personnel There are 18 people who have worked for AstraZeneca; the above-mentioned personnel accounted for 37% and 12% of the total number of employees of Dizhe Medicine at the end of 2020 respectively. In terms of patent transfer, in the current R&D pipeline of Dizhe Pharmaceutical, the compound patents of DZD4205, DZD2954 and DZD0095 are all purchased from AstraZeneca.
2. Although Dizhe Pharmaceuticals declares that it has always conducted business operations independently and has no dependence on AstraZeneca, it will continue to operate independently in the future and maintain an independent relationship with AstraZeneca in all aspects. . After many well-known capitals participated in the financing, as of before the IPO, Advanced Manufacturing and AZAB still held the same proportion of shares, both 30.2564%. Therefore, Dizhe Medicine has no ultimate actual controller; management ZYTZ and employee stock ownership plan* ** holds 17.3942%; Eli Lilly Asia Fund holds 9.9418% through LAV Dizal, Suzhou Likang, and Suzhou Lirui ***; Imagination V, which is actually controlled by Red Shirt Capital, holds 7.7326%, etc.
3. In terms of financial data, Dizhe Pharmaceutical achieved operating income of 39.4192 million yuan, 41.0175 million yuan, and 27.7608 million yuan in 2018, 2019, and 2020 respectively, and the net profits attributable to the parent company were -17361.40 respectively. million yuan, -445.7532 million yuan, and -586.6119 million yuan; of which R&D expenditures were 210.2042 million yuan, 421.4356 million yuan, and 439.4948 million yuan respectively.